AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23218851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact from a personal assistant providing contraception education, facilitation of insurance coverage, appointment scheduling, and assistance with childcare and transportation
Number of subjects: 50
Study 23218851 — intervention group
Group type: COMPARATOR
Intervention: Routine follow up
Number of subjects: 50
Study 21353749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (7.7±3.9 mg per day)
Number of subjects: 30
Study 21353749 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated, healthy volunteers)
Number of subjects: 30
Study 19592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount/moderate intensity exercise training
Number of subjects: 387
Study 19592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount/vigorous intensity exercise training
Number of subjects: 387
Study 19592624 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount/vigorous intensity exercise training
Number of subjects: 387
Study 19592624 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 387
Study 17615797 — intervention group
Group type: EXPERIMENTAL
Intervention: NM-702
Number of subjects: 386
Study 17615797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/2 ml antide (n=30)
Number of subjects: 144
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/ml antide (n=30)
Number of subjects: 144
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml antide (n=31)
Number of subjects: 144
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/0.5 ml antide (n=23)
Number of subjects: 144
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/ml antide (n=30)
Number of subjects: 144
Study 15333605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml antide (considered minimal effective dose)
Number of subjects: 144
Study 11214722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic-acid-enriched diet
Number of subjects: 8
Study 11214722 — intervention group
Group type: COMPARATOR
Intervention: Linoleic-acid-enriched diet
Number of subjects: 8
Study 9813513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion during rewarming stage of hypothermic CPB
Number of subjects: 120
Study 9813513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SNP infusion)
Number of subjects: 120
Study 10150723 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth training on the middle school tobacco prevention curriculum
Number of subjects: 0
Study 10150723 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 2687645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg i.m. every 3 weeks for 12 months + oral calcium supplement (1 g/day)
Number of subjects: 20
Study 2687645 — intervention group
Group type: COMPARATOR
Intervention: Placebo + oral calcium supplement (1 g/day)
Number of subjects: 20
Study 130058 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 298
Study 31778478 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin treatment (T1): Immature or newly emerged adults of P. solenopsis sprayed with kaolin and fed with cotton leaf discs treated with kaolin suspension.
Number of subjects: 0
Study 31778478 — intervention group
Group type: COMPARATOR
Intervention: Distilled water treatment (T2): Immature or newly emerged adults of P. solenopsis sprayed with distilled water and fed with cotton leaf discs treated with distilled water.
Number of subjects: 0
Study 31374033 — intervention group
Group type: EXPERIMENTAL
Intervention: 317-nursing mobile application program (317NAPP)
Number of subjects: 127
Study 31374033 — intervention group
Group type: COMPARATOR
Intervention: Telephonic consultations (control)
Number of subjects: 127
Study 25985405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother (triple regimen)
Number of subjects: 2369
Study 25985405 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant (nevirapine)
Number of subjects: 2369
Study 25985405 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither (no prophylaxis)
Number of subjects: 2369
Study 23962449 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/vinorelbine (GEMVIN)
Number of subjects: 0
Study 23962449 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/gemcitabine (PG)
Number of subjects: 0
Study 23962449 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/vinorelbine (PV)
Number of subjects: 0
Study 21293451 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg CP-945,598
Number of subjects: 3750
Study 21293451 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg CP-945,598
Number of subjects: 3750
Study 21293451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3750
Study 21293451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lifestyle and CP-945,598
Number of subjects: 3750
Study 21293451 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-945,598
Number of subjects: 3750
Study 19218298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercises
Number of subjects: 40
Study 19218298 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 40
Study 18603988 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thread loop
Number of subjects: 66
Study 18603988 — intervention group
Group type: COMPARATOR
Intervention: Non-loop group
Number of subjects: 66
Study 18603988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 15070094 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the stomach
Number of subjects: 11
Study 15070094 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the proximal small bowel
Number of subjects: 11
Study 15070094 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the distal small bowel
Number of subjects: 11
Study 15070094 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the ascending colon
Number of subjects: 11
Study 11704128 — intervention group
Group type: EXPERIMENTAL
Intervention: G1.2/G2.2 media
Number of subjects: 249
Study 11704128 — intervention group
Group type: COMPARATOR
Intervention: Sydney IVF media
Number of subjects: 249
Study 9385564 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 47‐0203, 30 mg/kg orally per day, two single doses
Number of subjects: 28
Study 9385564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study 8201835 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (rifampicin 40 mg/kg and 1200 mg clofazimine once)
Number of subjects: 622
Study 8201835 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 (rifampicin 40 mg/kg, clofazimine 100 mg, DDS 100 mg and ethionamide 500 mg once)
Number of subjects: 622
Study 8201835 — intervention group
Group type: COMPARATOR
Intervention: C2 and C4 (combined)
Number of subjects: 622
Study 2838442 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron boost irradiation (dose levels: 3.6, 4.2, 4.8, 5.2, 5.6, 6.0 Gyn gamma) along with whole brain photon irradiation (1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy)
Number of subjects: 190
Study 2838442 — intervention group
Group type: COMPARATOR
Intervention: Historical photon controls
Number of subjects: 190
Study 31197990 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA) assisted by mesh locator
Number of subjects: 94
Study 31197990 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of PFNA implantation
Number of subjects: 94
Study 28322476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment with more frequent sessions in a shorter period of time
Number of subjects: 700
Study 28322476 — intervention group
Group type: COMPARATOR
Intervention: Distributed sessions over longer time intervals
Number of subjects: 700
Study 26742305 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC) plus placebo for leflunomide (LEF)
Number of subjects: 45
Study 26742305 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide (LEF) plus XFC placebo
Number of subjects: 45
Study 23131133 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion with 50‐μm aluminum oxide
Number of subjects: 80
Study 23131133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (CoJet)
Number of subjects: 80
Study 23131133 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 80
Study 23131133 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 80
Study 21212367 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (370 mg of iodine per milliliter, n = 63)
Number of subjects: 130
Study 21212367 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol (320 mg of iodine per milliliter, n = 67)
Number of subjects: 130
Study 18078537 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2‐6 mg/day)
Number of subjects: 28
Study 18078537 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2‐40 mg/day)
Number of subjects: 28
Study 18078537 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 18078537 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol (both groups)
Number of subjects: 28
Study 17538084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (microdiskectomy)
Number of subjects: 283
Study 17538084 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with eventual surgery if needed
Number of subjects: 283
Study 15138461 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-enhanced formula with arginine and fiber (group I)
Number of subjects: 90
Study 15138461 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous formula with fiber (group II)
Number of subjects: 90
Study 11989571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin plus diet
Number of subjects: 19
Study 9219205 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cycle ergometer test at 50, 70, or 90 rpm
Number of subjects: 40
Study 8191901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 75% VO2max for 40 min
Number of subjects: 6
Study 8191901 — intervention group
Group type: COMPARATOR
Intervention: Exercise at 70-75% VO2max for 40 min after timolol ingestion
Number of subjects: 6
Study 3307976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 32
Study 3307976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31540737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal (CoM)
Number of subjects: 211
Study 31540737 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-metal (MoM)
Number of subjects: 211
Study 30535555 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Block (ESB)
Number of subjects: 44
Study 30535555 — intervention group
Group type: COMPARATOR
Intervention: Tumescent Anesthesia
Number of subjects: 44
Study 28583757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg at 6-hour intervals)
Number of subjects: 67
Study 28583757 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo at 6-hour intervals)
Number of subjects: 67
Study 26757748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX; anti‐CD20) treatment
Number of subjects: 30
Study 26757748 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 25178882 — intervention group
Group type: EXPERIMENTAL
Intervention: L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks
Number of subjects: 64
Study 25178882 — intervention group
Group type: EXPERIMENTAL
Intervention: L. salivarius TI 2711
Number of subjects: 64
Study 25178882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans)
Number of subjects: 64
Study 25178882 — intervention group
Group type: COMPARATOR
Intervention: xylitol
Number of subjects: 64
Study 22840410 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsuturing with 1 or 2 6/0 vicryl suture (n = 20)
Number of subjects: 40
Study 22840410 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 19622684 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 mg hydrocortisone (HCORT)
Number of subjects: 0
Study 19622684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17486686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed valerian hops extract combination (Ze 91019)
Number of subjects: 0
Study 17486686 — intervention group
Group type: COMPARATOR
Intervention: Single valerian extract (Ze 911)
Number of subjects: 0
Study 17486686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15114701 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib
Number of subjects: 102
Study 15114701 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day gefitinib
Number of subjects: 102
Study 15114701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 102
Study 15114701 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom improvement
Number of subjects: 102
Study 15114701 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 102
Study 11574339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 66
Study 11574339 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 66
Study 9595978 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple, isolated U-fiber lesions
Number of subjects: 53
Study 9595978 — intervention group
Group type: COMPARATOR
Intervention: No U-fiber lesions or only a single U-fiber lesion
Number of subjects: 53
Study 8151002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patch
Number of subjects: 0
Study 8151002 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicotine patch)
Number of subjects: 0
Study 3130371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory muscle training (isocapnic hyperpnea) for 30 min/day, 4 days/wk for 8 wk
Number of subjects: 25
Study 3130371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 30711905 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (PTT)
Number of subjects: 38
Study 30711905 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill training (CTT)
Number of subjects: 38
Study 30711905 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground gait analysis at T8
Number of subjects: 38
Study 28661816 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach messages emphasizing dental benefits
Number of subjects: 32993
Study 28661816 — intervention group
Group type: COMPARATOR
Intervention: Outreach messages emphasizing health benefits
Number of subjects: 32993
Study 25528078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (increase intake of fruits and vegetables, reduce red and processed meats) via telephone and printed materials
Number of subjects: 93
Study 25528078 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 93
Study 23791456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy for depression
Number of subjects: 105
Study 23791456 — intervention group
Group type: COMPARATOR
Intervention: Brief psychoeducational intervention
Number of subjects: 105
Study 21777954 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel with 20 mg esomeprazole
Number of subjects: 21
Study 21777954 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel
Number of subjects: 21
Study 21777954 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel with 150 mg ranitidine
Number of subjects: 21
Study 21777954 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 21
Study 20183542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold video
Number of subjects: 3
Study 20183542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain video
Number of subjects: 3
Study 20183542 — intervention group
Group type: EXPERIMENTAL
Intervention: Itchiness video
Number of subjects: 3
Study 17596252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 100
Study 15249570 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 mg subcutaneously twice daily)
Number of subjects: 31
Study 15249570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10650325 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/d orally)
Number of subjects: 80
Study 10650325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10650325 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 80
Study 9094066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid from GBS patients
Number of subjects: 2
Study 9094066 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid from CIDP patients
Number of subjects: 2
Study 8477064 — intervention group
Group type: EXPERIMENTAL
Intervention: MEVP therapy (10 mg/m2 of mitoxantrone intravenously on day 1, 2 mg/m2 of vindesine intravenously on day 1, 200 mg/m2 of etoposide orally on days 1-3, and 40 mg/m2 of prednisolone orally on days 1-5, repeated every 3 weeks for up to 10 courses)
Number of subjects: 57
Study 8477064 — intervention group
Group type: COMPARATOR
Intervention: CHOP therapy
Number of subjects: 57
Study 3513808 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16
Study 3513808 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 16
Study 3513808 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional diuretic treatment)
Number of subjects: 16
Study 29706129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 200
Study 29706129 — intervention group
Group type: COMPARATOR
Intervention: No cilostazol (Control)
Number of subjects: 200
Study 27528101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) monotherapy
Number of subjects: 322
Study 24509936 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised testimonials from rheumatologists and allied health professionals in the waiting room
Number of subjects: 2908
Study 24509936 — intervention group
Group type: COMPARATOR
Intervention: No TV (control group)
Number of subjects: 2908
Study 21946836 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with polydextrose (PDX) and galacto-oligosaccharides (GOS) (4 g/L, 1:1 ratio)
Number of subjects: 230
Study 21946836 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with PDX/GOS
Number of subjects: 230
Study 21946836 — intervention group
Group type: COMPARATOR
Intervention: Control (Enfamil Lipil)
Number of subjects: 230
Study 19574065 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular plating (group I)
Number of subjects: 35
Study 19574065 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel plating (group II)
Number of subjects: 35
Study 18422771 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen patches (Fem7, 100 microg)
Number of subjects: 14
Study 18422771 — intervention group
Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone agonist therapy
Number of subjects: 14
Study 15969877 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 205
Study 15969877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 12766246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 10
Study 10845571 — intervention group
Group type: EXPERIMENTAL
Intervention: 1628G‐‐>A (R485K) polymorphism of factor V
Number of subjects: 316
Study 10845571 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 316
Study 10845571 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 316
Study 8813896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides 5 g/d
Number of subjects: 24
Study 8813896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides 15 g/d
Number of subjects: 24
Study 8813896 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Control)
Number of subjects: 24
Study 8813896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (both doses)
Number of subjects: 24
Study 1553890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg once/day
Number of subjects: 45
Study 1553890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (0.4 mg orally every 6 hours for 48 hours)
Number of subjects: 63
Study 3890587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3890587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 63
Study 31836201 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 104
Study 31836201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)
Number of subjects: 104
Study 26936232 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks
Number of subjects: 34
Study 26936232 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily for 12 weeks
Number of subjects: 34
Study 26936232 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 34
Study 26936232 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily
Number of subjects: 34
Study 26850901 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 239